Gaithersburg-based MedImmune is expanding its recently announced research partnership with the University of Maryland, Baltimore to include two more UM campuses: College Park and Baltimore County.
MedImmune (the global biologics R&D arm of AstraZeneca) announced the five-year, $6 million collaboration with UMB in September 2013. The goal is to promote and advance the state’s capabilities in bioscience research.
On Tuesday, the company announced that the two other schools would be equally involved. MedImmune also identified the first five joint research projects that will be launched with the University System of Maryland.
In the company’s words, they are:
• Oncology: evaluate a molecule that simultaneously inhibits suppression of anti-tumor immunity and boosts activation of tumor-reactive T cells.
• Respiratory, Inflammation and Autoimmunity: evaluate the role of specific phagocytes in inflammatory diseases.
• Cardiovascular and Metabolic Disease: explore the mechanism and role of stem cells in cardiac regeneration.
• Infectious Diseases: explore the immune system-stimulating properties of key innate immune system proteins for use in novel vaccines.
• Infectious Diseases: study a novel nanoparticle vaccine delivery system with unique stability and immune-stimulating potential.